Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 3,009 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 3,009 shares of Insmed stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total transaction of $470,427.06. Following the completion of the transaction, the chief executive officer owned 303,882 shares in the company, valued at approximately $47,508,911.88. This trade represents a 0.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

William Lewis also recently made the following trade(s):

• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total value of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total value of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Trading Down 3.0%

NASDAQ INSM traded down $4.72 on Wednesday, hitting $152.44. 1,794,597 shares of the company were exchanged, compared to its average volume of 2,638,682. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The firm has a market capitalization of $32.51 billion, a P/E ratio of -24.63 and a beta of 1.11. The company’s 50 day moving average price is $178.14 and its 200-day moving average price is $159.71.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on INSM shares. Morgan Stanley upped their price target on shares of Insmed from $157.00 to $162.00 and gave the company an “equal weight” rating in a research report on Friday, January 30th. Barclays began coverage on shares of Insmed in a research note on Tuesday, January 27th. They set an “overweight” rating and a $231.00 target price on the stock. Bank of America raised their target price on Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Leerink Partners reiterated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Finally, Citigroup reissued an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Insmed currently has a consensus rating of “Buy” and a consensus price target of $206.04.

Hedge Funds Weigh In On Insmed

Several institutional investors and hedge funds have recently modified their holdings of INSM. CoreCap Advisors LLC purchased a new stake in shares of Insmed during the fourth quarter worth $27,000. GraniteShares Advisors LLC purchased a new position in Insmed in the fourth quarter valued at about $30,000. CIBC Private Wealth Group LLC increased its position in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. Stone House Investment Management LLC acquired a new position in Insmed in the 3rd quarter worth about $29,000. Finally, SBI Securities Co. Ltd. raised its stake in shares of Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.